NY-ESO-1-specific T-cells - Adaptimmune

Drug Profile

NY-ESO-1-specific T-cells - Adaptimmune

Alternative Names: '794; GSK 3377794; NY-ESO SPEAR T-cell therapy; NY-ESO TCR therapeutic; NY-ESO-1 T cell receptor; NY-ESO-1/LAGE-1-modified T-cells; NY-ESO-1/LAGE-1-specific T-cells - Adaptimmune

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Adaptimmune
  • Developer Adaptimmune; GlaxoSmithKline
  • Class Antineoplastics; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Synovial sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastrointestinal cancer; Malignant melanoma; Multiple myeloma; Ovarian cancer
  • Phase I/II Liposarcoma; Non-small cell lung cancer; Synovial sarcoma
  • No development reported Liver cancer; Prostate cancer

Most Recent Events

  • 13 Mar 2017 Adaptimmune Therapeutics has patent protection for NY-ESO SPEAR T-cell in Australia, Switzerland, Germany, Denmark, France, United Kingdom, Ireland and the Netherlands, New Zealand, Japan and the USA
  • 05 Dec 2016 Phase-I/II clinical trial in Liposarcoma (Myxoid round cell liposarcoma; Metastatic disease, Inoperable/Unresectable) in USA (IV)
  • 09 Nov 2016 The US FDA removes a partial clinical hold on a planned pivotal study of NY-ESO-1-specific T-cell therapy for myxoid round cell Liposarcoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top